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Abstract
Although borderline personality disorder (BPD) traits decline from adolescence to adulthood, 
comorbid psychopathology such as symptoms of major depressive disorder (MDD), alcohol use 
disorder (AUD), and drug use disorders (DUDs) likely disrupt this normative decline. Using a 
longitudinal sample of female twins (N = 1,763), we examined if levels of BPD traits were 
correlated with changes in MDD, AUD, and DUD symptoms from ages 14–24. A parallel process 
biometric latent growth model examined the contributions of genetic and environmental factors to 
the relationships between developmental components of these phenotypes. Higher BPD trait-levels 
predicted a greater rate of increase in AUD and DUD symptoms, and higher AUD and DUD 
symptoms predicted a slower rate of decline of BPD traits from ages 14–24. Common genetic 
influences accounted for the associations between BPD traits and each disorder, as well as the 
interrelationships of AUD and DUD symptoms. Both genetic and nonshared environmental 
influences accounted for the correlated levels between BPD traits and MDD symptoms, but solely 
environmental influences accounted for the correlated changes between the two over time. Results 
indicate that higher levels of BPD traits may contribute to an earlier onset and faster escalation of 
AUD and DUD symptoms, and substance use problems slow the normative decline in BPD traits. 
Overall, our data suggests that primarily genetic influences contribute to the comorbidity between 
BPD features and substance use disorder symptoms. We discuss our data in the context of two 
major theories of developmental psychopathology and comorbidity.
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Borderline personality disorder (BPD) is characterized by affective instability, impulsivity, 
impaired social functioning, and identity disturbance (American Psychiatric Association, 
2013). BPD is related to a number of negative outcomes including interpersonal and 
occupational impairment, and suicide (Skodol et al., 2002). Particularly concerning are the 
high rates of comorbidity between BPD and other psychiatric disorders, including major 
depressive disorder (MDD), alcohol use disorder (AUD), and illicit drug use disorders 
(DUD) (McGlashan et al., 2000; Zanarini et al., 2004; Zimmerman & Mattia, 1999). For 
those who meet diagnostic criteria for BPD, lifetime comorbidity rates with MDD and AUD 
or DUD have been reported as high as 32.1% and 30.9%, respectively (Grant et al., 2008). 
Moreover, the association between BPD and several areas of functional impairment can be 
attributed to a general impairment shared between BPD and MDD, AUD, and DUDs 
(Lenzenweger, Lane, Loranger, & Kessler, 2007), although there is evidence that BPD 
predicts functional impairment over-and-above co-morbid psychopathology (Skodol et al., 
2002). In order to better inform treatment frameworks for BPD, it is especially important to 
investigate the developmental origins and etiological influences that contribute to this 
comorbidity.
Normative Developmental Change
In epidemiological samples, BPD prevalence and trait levels decline from mid-adolescence 
into young adulthood (Bernstein et al., 1993; Bornovalova, Hicks, Iacono, & McGue, 2009; 
Cohen, Crawford, Johnson, & Kasen, 2005; Johnson et al., 2000; Lenzenweger, 1999). 
There is also evidence for similar declines in adolescents and adults with clinically elevated 
levels of BPD symptoms (Cohen et al., 2005; Grilo et al., 2004; Johnson et al., 2000; 
Lenzenweger, 1999; Meijer, Goedhart, & Treffers, 1998; Paris, Brown, & Nowlis, 1987; 
Shea et al., 2002; Zanarini, Frankenburg, Hennen, & Silk, 2003). The normative decline in 
BPD levels is likely due to developmental changes associated with personality maturation. 
Indeed, declines in the normal range personality traits of negative emotionality and 
behavioral disinhibition – traits that are core to the definition of BPD – show most 
pronounced changes from late adolescence to young adulthood (Durbin et al., 2016; Johnson 
et al., 2007; Roberts, Caspi, & Moffitt, 2001). In contrast, MDD prevalence rates spike in 
mid-adolescence and increase into young adulthood, after which they remain relatively 
stable. Risk for AUD and DUD increases in late adolescence, peaks in young adulthood, and 
then shows a substantial decline by age 30 (Chassin, Flora, & King, 2004; Compton, 
Thomas, Stinson, & Grant, 2007; Costello, Mustillo, Erkanli, Keeler, & Angold, 2003; 
Merikangas et al., 2010; Wittchen, Nelson, & Lachner, 1998). The rise and subsequent 
decline in AUD and DUD symptoms likely represents extreme versions of maturational 
changes in behavioral disinhibition. Likewise, the rise in MDD symptoms during 
adolescence likely represents maladaptive variation in neuroticism and social problem-
solving (Keller & Nesse, 2005; Moffitt, 1993; Nettle, 2006; Watson & Andrews, 2002).
Evidence for Common Cause, Predisposition, and Pathoplasty Models
Several models have been proposed to account for personality-psychopathology 
associations, most notably the predisposition, pathoplasty, and common cause models 
(Durbin & Hicks, 2014). The predisposition model posits that BPD traits increase risk for 
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the onset of a new disorder. The pathoplasty model predicts that BPD traits affect the course 
of disorders, such that higher BPD traits contribute to greater severity and/or chronicity of a 
disorder. The common cause model posits that some third variable, such as emotion 
dysregulation or disinhibition, accounts for the comorbidity between BPD traits and other 
disorders. While each of these models could independently account for BPD-
psychopathology associations, it is important to note that they can operate simultaneously. 
Also, these models ignore normative developmental shifts in the mean-levels of traits and 
the prevalence of disorders, and thus do not account for how these age-related changes might 
contribute to the comorbidity between BPD traits and other disorders.
The common cause model has received the majority of empirical attention and suggests that 
BPD traits and symptoms of comorbid disorders are derived partly from shared 
neurobiological influences. Seminal theories posit that BPD traits result partly from the 
interplay between the same environmental risk (e.g., traumatic life events) and pre-existing, 
biologically influenced tendencies that exacerbate comorbid disorders, such as negative 
emotionality, sensitivity to emotional cues, and behavioral disinhibition (Linehan, 1993). 
Given that impulsivity is related to BPD traits, AUD, and DUD symptoms throughout 
development, it has received special attention in efforts to identify a common diathesis 
(Berlin, Rolls, & Iversen, 2005; Brodsky et al., 2001; De Wit, 2009; Dick et al., 2010). 
Recent models of BPD further emphasize developmental processes that contribute to 
heterotypic continuity (Kaufman, Crowell, & Stepp, 2015) and include evidence from 
behavior genetic methodology and neuroimaging to support the notion that impulsivity is a 
common feature of BPD traits and AUD and DUD symptoms (Beauchaine, Klein, Crowell, 
Derbidge, & Gatzke-Kopp, 2009; Crowell, Beauchaine, & Linehan, 2009). These models 
posit that the expression of an underlying biological system for a phenotype, such as trait 
impulsivity (Coccaro et al., 1989; Friedel, 2004), can gives rise to multiple maladaptive 
phenotypic outcomes in the context of other biological and environmental influences 
(Beauchaine et al., 2009). Similarly, neuroticism has been considered as one possible source 
in BPD-MDD comorbidity (Distel et al., 2009; Hettema, Neale, Myers, Prescott, & Kendler, 
2006; Soldz, Budman, Demby, & Merry, 1993; Trull, 1992; Clarkin, Hull, Cantor, 
Sanderson, 1993; Soldz, Budman, Demby, & Merry, 1993).
Building on well-established evidence that differences in neural responses to rewarding 
stimuli covary with impulsivity (Martin & Potts, 2004; Wilbertz et al., 2012), recent 
neuroimaging evidence suggests that reduced activation in neural regions that process 
rewards are associated with higher levels of BPD traits, such as self-injurious behavior 
(Sauder, Derbidge, & Beauchaine, 2016). Similar findings have been observed in 
participants with MDD symptoms and elevated alcohol or substance use (Beck et al., 2009; 
Jentsch & Taylor, 1999; Must et al., 2006). Further evidence suggests that BPD patients and 
participants with lesions in brain regions associated with reward processing, such as the 
orbitofrontal cortex, exhibit elevated impulsivity, inappropriate behavior, and other common 
BPD characteristics compared with a control group (Berlin, Rolls, & Iversen, 2005; Forbes 
et al., 2009). With respect to the BPD-MDD comorbidity, recent neuroimaging work 
suggests that variability in structure and function of the prefrontal cortex, anterior cingulate, 
hippocampus, and amygdala may represent a neurobehavioral risk factor for development of 
neuroticism that has downstream effects on BPD and MDD comorbidity (Cremers et al., 
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2010; Davidson, Pizzagalli, Nitschke, & Putnam, 2002; DeYoung et al., 2010; Driessen et 
al., 2000; Haas, Omura, Constable, & Canli, 2007; Hazlett et al., 2005; Soloff et al., 2003; 
Tzschoppe et al., 2014). These data emphasize the importance of neurodevelopmental 
influences on BPD and commonly comorbid psychopathology, and provide suggestive 
evidence that the common cause model may partially explain co-development and change in 
BPD traits and symptoms of comorbid psychopathology. However, a longitudinal test of the 
common cause model is needed.
In a prior study with a subset of the present sample, we provided a test of the predisposition 
model for BPD traits and a composite of substance use (tobacco, alcohol, and marijuana 
quantity and frequency) in 14 and 18 year old female twins (Bornovalova, Hicks, Iacono, & 
McGue, 2013). BPD traits and substance use were correlated at each age, but BPD traits at 
age 14 did not predict substance use at age 18 after accounting for the stability of BPD traits 
and substance use (and vice versa). These results were consistent with a common cause but 
not predisposition model; however, they failed to rule out the pathoplasty model. 
Additionally, while this study focused on quantity and frequency of substance use, it did not 
examine the association with substance use disorder symptoms.
Finally, there is accumulating evidence for the pathoplasty model. For example, recurrent or 
chronic MDD is associated with a failure to exhibit normative declines in the personality 
trait of stress reaction, while persistent AUD is associated with a lack of normative decline 
in aggression and behavioral disinhibition (Durbin & Hicks, 2014). Given the strong 
connection between BPD traits and these normal-range personality traits, it is also likely that 
BPD traits will fail to decline when accompanied by chronic MDD and substance use 
disorder symptoms; conversely, the remission of comorbid disorders may facilitate a 
reduction in BPD traits. For instance, a large community sample of adolescent females 
reported that increasing BPD symptoms were associated with worsening social and mental 
health outcomes (Wright, Zalewski, Hallquist, Hipwell, & Stepp, 2015). Likewise, adult 
clinical samples report that the rate of decline in BPD traits is associated with the rate of 
decline for the personality trait of neuroticism (Wright, Hopwood, & Zanarini, 2015), as 
well as decline in co-occurring MDD, AUD, and DUD symptoms (De Panfilis et al., 2011; 
Gunderson et al., 2008; Zanarini et al., 2011; Zanarini Frankenburg, Hennen, Reich, & Silk, 
2004). Data from the Collaborative Longitudinal Personality Disorder Study, for instance, 
indicated that patients with BPD and MDD negatively impacted each other’s time to 
remission and accelerated time to relapse (Grilo et al., 2005; Gunderson et al, 2014); similar 
results have been reported for substance use disorders (Walter et al., 2009). Likewise, results 
from the McLean Study of Adult Development have repeatedly documented that initial 
levels and remission status in BPD predict change in major depressive, drug, and alcohol use 
disorders (and vice versa; Frankenburg, Fitzmaurice, & Zanarini, 2014; Zanarini et al., 2004; 
Zanarini et al, 2011; Zanarini, Frankenburg, Hennen, Reich, & Silk, 2005).
Current Study
We sought to advance our understanding of the association between BPD traits and 
symptoms of comorbid disorders in a number of ways. First, we focused on examining both 
the pathoplasty and common cause models of BPD traits and AUD, DUD, and MDD 
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symptoms (due to the lack of support in our prior research with this sample, we did not 
examine the predisposition model). By including symptoms of multiple disorders we were 
able to examine convergent and discriminant processes contributing to BPD trait-levels and 
symptoms of commonly co-occurring disorders. Second, we extended the developmental 
period of interest from age 14 to 24, a period when there are declines in BPD traits and large 
increases in MDD, AUD, and DUD symptoms. Notably, most studies that have examined the 
comorbidity between BPD traits and other disorders have used adult samples (Gunderson et 
al., 2008; Zanarini et al., 2004) with less developmental change in these traits and disorders. 
Third, we used our twin sample to estimate genetic and environmental contributions to BPD 
traits and their overlap with symptoms of the disorders. Several large cross-sectional studies 
have investigated both the heritability of BPD traits (Distel et al., 2011; Distel et al., 2009; 
Distel et al., 2008; Kendler et al., 2008; Kendler et al., 2011; Reichborn-Kjennerud et al., 
2015; Reichborn-Kjennerud et al., 2010; Torgersen et al., 2008; Torgersen et al., 2000) as 
well as the genetic and environmental overlap between BPD traits and MDD, AUD, and 
DUD symptoms in adults (Distel et al., 2012; Kendler et al., 2011). The current study 
extends this work to modeling the etiological influences on longitudinal relationships as 
well. Finally, we modeled the cross-sectional and longitudinal relationships between BPD 
features and MDD, AUD, and DUD symptoms simultaneously. This allowed us to test the 
common cause and pathoplasty models for multiple disorders, thereby connecting the 
current study to the broader developmental psychopathology literature.
A small but growing literature indicates that BPD tendencies are influenced roughly equally 
by additive and non-additive genetic (35–50%) and non-shared environmental (50–60%) 
sources (Distel et al., 2009; Distel et al., 2008; Kendler et al., 2008; Kendler et al., 2011), 
Genetic factors account for much of the association between BPD traits with AUD and DUD 
symptoms in adults (Bornovalova et al., 2013; Distel et al., 2012; Kendler et al., 2011), 
whereas the association with MDD symptoms is largely accounted by environmental factors 
(Kendler et al., 2011). These previous studies have been almost exclusively cross-sectional 
and focused on adults. We hoped to extend this work to the co-development between BPD 
traits and symptoms of multiple disorders from mid-adolescence through young adulthood.
We also capitalized on the longitudinal nature of the data to fit biometric latent growth 
models to better understand the co-development between BPD traits and symptoms of 
MDD, AUD, and DUD (as well as the interrelationships within MDD, AUD, and DUD 
symptoms). Evidence consistent with the common cause model exists if there are significant 
correlations between the intercepts (average levels) and slopes (linear rate of change) for 
BPD traits and symptoms of MDD, AUD, and DUD. Common cause would also be inferred 
if common genetic or environmental influences accounted for any of the cross-sectional or 
longitudinal relationships between BPD traits and MDD, AUD, and DUD symptoms. 
Evidence consistent with the pathoplasty model exists if the intercept for BPD traits are 
correlated with the slopes of MDD, AUD, and DUD symptoms (and vice versa); that is, if 
average levels of BPD traits predicted a more severe course (i.e., greater increase) in 
symptoms of the disorder. Likewise, pathoplasty would be inferred if high average levels of 
MDD, AUD, and DUD symptoms are associated with a lack of normative declines in BPD 
trait levels (i.e., shallower slopes).
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Method
Sample
Participants were adolescent female twins taking part in the Minnesota Twin Family Study 
(MTFS), an ongoing population-based, longitudinal study of twins and their families 
(Iacono, Carlson, Taylor, Elkins, & McGue, 1999; Keyes et al., 2009). Birth records and 
public databases were used to locate more than 90% of families that included a twin birth in 
the state of Minnesota from 1975 to 1984 and 1988 to 1994. Eligible twins and their families 
were a) living within a one-day drive of Minneapolis with at least one biological parent, and 
b) had no mental or physical handicap precluding participation. All protocols were approved 
by the institutional review board. Parents and children gave informed consent or assent as 
appropriate.
The MTFS intake sample includes an 11-year-old and a 17-year-old cohort consisting of 
same-sex male and female monozygotic (MZ) and dizygotic (DZ) twins. The current study 
focused on the female twins, as the male twins only had BPD data at two assessment time 
points. Intake and follow-up assessments are scheduled to coincide with major transitions in 
the lives of adolescents and young adults. BPD traits were first assessed at age 14 for the 
younger cohort, and at age 17 for the older cohort. Follow-up assessments of BPD traits 
were conducted at age 17 and 24 in the younger cohort and at ages 20 and 24 in the older 
cohort. In the current study, the cohorts were combined and matched by age of assessment. 
The actual ages at each assessment (corrected for in all analyses) were 14.88 (SD = .57), 
17.89 (SD = .69), 20.83 (SD = .61), and 25.09 (SD = .73). AUD, DUD, and MDD symptoms 
were assessed using the same time points and procedures, then combined and corrected for 
age variability in the same manner as BPD traits. Retention rates were excellent with 
approximately 90% participation at each wave.
The final sample included 1121 MZ (or identical) twins and 642 DZ (or fraternal) twins. The 
sample sizes for each assessment time point were as follows: age 14 (N = 1080; 674 twins 
from MZ pairs, 406 twins from DZ pairs); age 17 (N = 1602; 1026 twins from MZ pairs, 
576 twins from DZ pairs); age 20 (N = 1389; 879 twins from MZ pairs, 510 twins from DZ 
pairs); age 24 (N = 1260; 797 twins from MZ pairs, 463 twins from DZ pairs). Zygosity was 
determined by agreement among 3 estimates: MTFS staff evaluations of the twins’ physical 
similarity; parents’ completion of a standard zygosity questionnaire; and twin similarity on 
an algorithm of ponderal and cephalic indices and fingerprint ridge count. A serological 
analysis was performed if the 3 estimates did not agree. Consistent with the racial/ethnic 
makeup of the recruitment area, 95.3% of the sample was white. Additionally, the mean 
maternal and paternal years of education among the families of origin were 13.57 (2.09) and 
13.67 (2.61), respectively.
Measures
BPD Traits—The Minnesota Borderline Personality Disorder Scale (MBPD; Bornovalova, 
Hicks, Patrick, Iacono, & McGue, 2011) is a self-report inventory of BPD traits that 
provides a dimensional measure of BPD trait severity. The MBPD was developed using 
items from the Multidimensional Personality Questionnaire (MPQ; Tellegen, 1982; Patrick, 
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Curtin, & Tellegen, 2002) and asks participants to respond to 19-items on a 4-point scale 
(agree, somewhat agree, somewhat disagree, disagree). Items for the MBPD were selected 
due to overlap with BPD symptomatology and were drawn from the following MPQ scales: 
stress reaction (e.g., Mood often fluctuates), alienation (e.g., Often betrayed by friends), 
control (e.g., Often act impulsively), aggression (e.g., Sometimes enjoy saying mean things), 
well-being (e.g., Rarely feel happy), and absorption (e.g. Sometimes feel presence of people 
not actually there). While the MPQ was designed to measure normal personality 
functioning, the MBPD scale is correlated with established self-report measures of BPD 
traits (rs= 0.80–0.89) and BPD diagnosis and symptom counts (rs = 0.60–0.66, respectively) 
from structured interviews in community and clinical samples (Bornovalova et al., 2011; 
Rojas et al., 2014; Rojas, Hicks, Stark, Hopwood, & Bornovalova, 2015). MBPD scores also 
show high reliability and temporal stability (Rojas et al., 2015) as well as theoretically 
expected associations with criterion variables in the BPD trait nomological network, such as 
impulsivity, antisocial behaviors, interpersonal problems, MDD symptoms, and alcohol and 
drug use (Bornovalova et al., 2011; Bornovalova et al., 2013; Rojas et al., 2013; Rojas et al., 
2015). In this sample, internal consistency reliability was > .80 for all follow-ups, and the 
score distributions exhibited minimal skew and kurtosis (< 1 for all time points). Therefore, 
MBPD scores can be used to make reasonable inferences about BPD traits. To adjust for any 
variability in age at each assessment, the BPD trait data were conditioned on target age (ages 
14, 17, 20, or 24 depending on the assessment wave; i.e., age variability around each 
assessment point regressed out; Bornovalova et al., 2009; Johnson et al., 2007). Raw scores 
are plotted for descriptive purposes in Figure 1. To aid with model fitting in all non-
descriptive analyses, MBPD scores were recoded to range between 1 (maximum possible 
score) and 0 (minimum possible score) using the following equation: [(MBPD individual 
score-min)/(max-min) = (MBPD individual score-19)/57]. This rescaling minimized the 
differences in variance between the variables in the models while maintaining all the original 
properties of the MBPD scores.
MDD, AUD and DUD Symptoms—Symptoms of MDD, AUD, and DUD were assessed 
using the Diagnostic Interview for Children and Adolescents – Revised (DICA-R) (Reich & 
Welner, 1988), the Structured Clinical Interview for DSM-III-R (Spitzer, Williams, Gibbon, 
& First, 1987), and the Substance Abuse Module of the Composite International Diagnostic 
Interview (Robbins, Cottler, & Babor, 1990). Clinical interviews were conducted by trained 
staff members at the University of Minnesota. Maternal reports of these symptoms were also 
collected at ages 14 and 17. Consistent with evidence that each informant provides unique 
information in the assessment of psychopathology, we utilized a best estimate approach and 
considered a symptom present if reported by either the twin or parent (Burt, Krueger, 
McGue, & Iacono, 2003; Burt, Krueger, McGue, & Iacono, 2001). An established diagnostic 
consensus procedure was used to maximize accuracy of symptom assignment. For each 
participant, a clinical case conference consisting of at least two advanced clinical 
psychology graduate students was conducted in which all interview data was reviewed, 
referring to audiotapes when necessary. The two diagnosticians were required to reach 
consensus regarding symptom presence prior to assigning any symptoms. Once consensus 
was reached regarding the presence/absence of symptoms, a computer algorithm was used to 
determine diagnosis. The consensus process yielded diagnostic kappa reliabilities that 
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ranged from 0.71 to 0.92. All symptom counts were log transformed to reduce skew and 
kurtosis (see Table 1 for means and SDs, as well as the range of the raw and log-transformed 
scales). As with MBPD scores, the MDD, AUD, and DUD data were conditioned on target 
age to account for any variability in age at each assessment.
Analytic Approach
We fit a multivariate biometric latent growth model to BPD traits and MDD, AUD, and 
DUD symptoms between the ages of 14 and 24. This model allows us to simultaneously 
model the developmental trajectories of each phenotype using a set of latent factors that 
estimate the average level (intercept) and rate of change (both linear and quadratic) in each 
phenotype, as well as the covariance between the latent growth parameters (Molenaar & 
Rovine, 1998; Neale & McArdle, 2000; Singer & Willett, 2003).12 Multivariate growth 
models allowed us to examine the covariance between the latent growth parameters across 
phenotypes, such as a) the correlation between the intercept of BPD traits and the intercept 
of the other phenotypes (e.g., do people with higher levels of BPD traits have more 
symptoms of other psychopathology?); b) the correlation between the linear slope of BPD 
traits and the linear slope of the other phenotypes (e.g., do people who decrease in BPD 
traits more slowly also have a faster rate of increase in other symptoms of 
psychopathology?), c) the correlation between the intercept of BPD traits and the linear 
slope of the other phenotypes (e.g., do people with higher BPD traits increase faster in AUD 
symptoms?); d) the correlation between the linear slope of BPD traits and the intercept of 
the other phenotype (e.g., do BPD traits decrease more slowly among people with higher 
average levels of AUD symptoms?). (a) and (b) provide evidence for common cause, 
whereas (c) and (d) provide evidence of pathoplasty.
We used the twin data to decompose the variance of the latent growth parameters into 
additive genetic (A - additive effect of individual genes summed over loci on trait variance), 
shared environmental (C - environmental influences that increase similarity between 
members of a twin pair), and unshared environmental (E - environmental factors that 
contribute to differences between members of a twin pair, including measurement error) 
variance components. This allowed us to examine genetic and environmental influences on 
the co-development between BPD traits and MDD, AUD, and DUD symptoms. To 
determine the best fitting model for each phenotype, we progressively dropped parameters 
for the variance components and time specific residuals and compared model fit of nested 
models to identify a parsimonious model that was consistent across all four phenotypes (see 
supplemental materials for model-fitting results). Because the common environmental 
factors did not significantly improve the fit of any models, we present the results with these 
parameters fixed at zero. Finally, we estimated the genetic and environmental contributions 
to covariance between growth parameters for BPD traits and the other phenotypes. A path 
depiction of the bivariate growth model for one twin (which generalizes to the multivariate 
1For these models, factor loadings on the latent growth factors varied to account for differing measurement intervals. Also, orthogonal 
polynomial contrast weights were used for the linear and quadratic loadings to remove non-essential multicollinearity between the 
latent factors. The intercept was anchored at the age midpoint (~age 19).
2Negligible variance for higher-order growth factors – such as quadratic growth factors – is common and correlations with parameters 
with virtually zero variance are generally uninformative and can lead to empirical under-identification. Accordingly, the models 
estimated the variance of the quadratic parameter but not the covariance of the quadratic parameter with the intercept or linear factors.
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case) is presented in Figure 1. All models were fit with Full Information Maximum 
Likelihood (which is robust to most forms of missingness) in OpenMx 2.0 (Little & Rubin, 
1983; Neale et al., 2016).
Results
Within Trait Biometric Latent Growth Parameters
Descriptive statistics for all of the variables, such as means, standard deviations, and twin 
correlations by zygosity for all phenotypes and ages are reported in Table 1. We present the 
means, variances, and proportion of additive genetic (A) and unique environmental (E) 
variance of the latent growth factors for each phenotype in Table 2, and a spaghetti plot of 
the trajectories of each phenotype in Figure 2. Consistent with our previous report, the 
negative slope for BPD traits indicated that trait BPD significantly decreased from ages 14 to 
24 (Bornovalova et al., 2009). In contrast, MDD, AUD, and DUD symptoms all had positive 
linear slopes, indicating that on average there was an increase in symptoms for each disorder 
from ages 14 to 24. Biometric model fitting (Table 3) indicated that the best fitting biometric 
models included only genetic and nonshared environmental components for the latent 
growth factors and residual variances of each phenotype at each assessment. Results from 
the biometric variance decompositions (Table 2) revealed that the intercept of each 
phenotype was highly heritable (0.64 to 0.78) with small to medium nonshared 
environmental influences (0.36 to 0.22). The linear slope for BPD traits and AUD and DUD 
symptoms exhibited significant genetic influences (0.33 to 0.65), while the linear slope for 
MDD symptoms was mostly determined by non-shared environment influences (0.82). 
Finally, although the quadratic variance component did not have sufficient variation to 
reliably decompose into genetic and environmental influences, it improved model fit and 
was subsequently retained in all models3 .
Cross-Phenotype Biometric Latent Growth Parameters
Table 4 presents the phenotypic correlations, Table 5 presents the additive genetic 
correlations, and Table 6 presents the unique environmental correlations for the growth 
parameters across the four phenotypes. Because we focused on the relationship between 
BPD traits and the three other phenotypes, the first two columns of Tables 4–6 are of 
primary interest. The other columns speak to broader co-development of MDD, AUD, and 
DUD symptoms.
Evidence for common cause—Consistent with the common cause model, the BPD trait 
intercept was significantly correlated with the intercepts for MDD, AUD, and DUD 
symptoms, indicating that those with higher BPD trait levels tended to experience more 
symptoms of MDD, AUD, and DUD. The intercept for BPD traits showed significant 
genetic and moderate nonshared environmental correlations with the intercepts of MDD, 
AUD, and DUD symptoms (Tables 4 and 5), indicating greater genetic relative to 
environmental overlap between BPD traits and the other phenotypes. A similar pattern was 
3The confidence intervals for the quadratic term were large and included both 0 and 1. In our models, its correlation with other growth 
parameters was fixed to zero. The intercept-slope correlations of the individual phenotypes was included in the models and is reported 
elsewhere (Bornovalova et al, 2009).
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evident for MDD, AUD, and DUD symptoms: the intercepts were significantly correlated 
with each other, and evidenced similar pattern of genetic and environmental covariation.
Next, the linear slope for BPD traits was correlated with the linear slopes for MDD, AUD, 
and DUD symptoms. This indicates that after accounting for the average level, greater 
increases in symptoms of MDD, AUD, and DUD were associated with a slower decline in 
BPD traits. Alternatively, this could be stated as the smaller the increase in symptoms of 
MDD, AUD, and DUD, the greater the decline in BPD traits. The genetic correlation 
between the slopes was significant and of moderate effect, while the nonshared 
environmental correlations were not significant, with one notable exception. The nonshared 
environmental correlation between BPD trait slope and MDD symptom slope was moderate 
(.47) and significant. No other nonshared environmental correlations approached 
significance. Therefore, genetic influences primarily accounted for the associations between 
the linear slopes of BPD traits and AUD and DUD symptoms. In contrast, nonshared 
environmental influences primarily accounted for the association between the linear slopes 
of BPD traits and MDD symptoms. With respect to other phenotypes, MDD symptom slope 
predicted AUD but not DUD symptom slope. This relationship was accounted for by 
overlapping genetic factors, with no significant evidence for nonshared environmental 
overlap. AUD and DUD symptom slopes were significantly correlated, showing strong and 
roughly equal influences of common genetic and nonshared environmental factors.
Evidence for pathoplasty—The intercept for BPD traits was correlated with the linear 
slope of AUD and DUD symptoms, but not MDD symptoms. Consistent with the 
pathoplasty hypothesis, individuals who had higher levels of BPD traits increased in AUD 
and DUD symptoms more rapidly. Furthermore, the nonshared environmental correlations 
between BPD trait intercept and the linear slopes of AUD and DUD symptoms were 
significant and contributed more to the covariance than genetic factors. The linear slope for 
BPD traits was negatively correlated with the intercepts of AUD and DUD symptoms, and 
unrelated to the MDD symptoms intercept. This indicates that individuals with more AUD 
and DUD symptoms were associated with a slower rate of decline in BPD traits, even after 
adjusting for the average trait level. The associations between the linear slope of BPD traits 
and the intercepts of AUD and DUD symptoms were almost entirely due to genetic 
influences. As for the other phenotypes, MDD symptom intercept was positively correlated 
with AUD and DUD symptom slope (but not vice versa), with this relationship accounted 
for solely by genetic overlap. Unsurprisingly, AUD symptom intercept was correlated with 
DUD symptom slope (and vice versa), with somewhat more robust nonshared environmental 
than genetic overlap. Taken together, the slope-intercept correlations across all four 
phenotypes suggest that an individual’s comorbid psychopathology is associated with the 
trajectory of other maladaptive traits.
Discussion
Using a large, longitudinal twin sample, we conducted the first study to investigate the 
genetic and environmental influences on the co-development between BPD traits and MDD, 
AUD, and DUD symptoms from middle adolescence to young adulthood. Previous studies 
have reported that BPD traits tend to decline over time, and that declines in BPD traits are 
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associated with declines in the symptoms of comorbid disorders (Bornovalova et al., 2009; 
Gunderson et al., 2008; Lenzenweger, 1999). Few studies, however, have considered the 
developmental context of the associations between BPD traits and symptoms of other 
disorders—specifically, during a period when there are dramatic changes in the mean-levels 
of BPD traits, MDD, AUD, and DUD symptoms—allowing for hypotheses about 
developmental processes that might contribute to these associations. Next, no study has 
examined the genetic and environmental influences on the co-development between BPD 
traits and symptoms of other disorders. Finally, the current paper simultaneously modeled 
the total, genetic, and nonshared environmental correlations between BPD traits, MDD, 
AUD, and DUD symptoms. Results from this model align the current paper with the broader 
models within developmental psychopathology that suggest that disorders rarely develop 
discretely and independently. Rather, there is an interdependence and interaction among 
multiple forms of psychopathology that necessitate a whole-organism approach.
In terms of developmental change, we replicated previous epidemiological findings that 
BPD traits decreased, while symptoms of MDD, AUD, and DUD increased from ages 14 to 
24 (Chen & Jacobson, 2012; Dussault, Brendgen, Vitaro, Wanner, & Tremblay, 2011). The 
decline in BPD traits was consistent with longitudinal research on normal personality 
development that finds large declines in negative emotionality and behavioral disinhibition 
during the transition from adolescence into young adulthood (Johnson et al., 2000; Roberts, 
Walton, & Viechtbauer, 2006). Our findings suggest similar maturational processes may 
contribute to age-related declines in BPD traits.
The current results support two models of comorbidity: the common cause model and the 
pathoplasty models. For common cause, we detected medium to large associations between 
a) the average level of BPD traits and the average levels of the other disorders and b) 
changes in BPD traits and changes in other disorders associations. Consistent with previous 
work (Distel et al., 2012; James & Taylor, 2008; Kendler et al., 2011), these associations 
were primarily due to genetic influences. Beyond BPD, there were large genetic correlations 
between MDD, AUD, and DUD as well. The data suggest that there are transdiagnostic, 
heritable influences (e.g., temperament traits) that contribute to the average level as well as 
the covariation in change of BPD traits, MDD, AUD, and DUD symptoms from ages 14 to 
24.
Importantly, correlated rates of change provide especially strong evidence of a common 
cause model, suggesting that a similar process is affecting fluctuations in both BPD traits 
and symptoms of other psychopathology. Also consistent with a common cause model, there 
was substantial genetic and environmental overlap between the intercepts and slopes among 
BPD traits, AUD, DUD, and MDD symptoms. Interestingly, genetic influences primarily 
accounted for the correlated changes between BPD traits and AUD and DUD symptoms, 
while environmental influences primarily accounted for the correlated changes between 
BPD traits and MDD symptoms. Also, the correlations between the slope for BPD traits and 
the changes in AUD and DUD symptoms were small, while the correlation between the 
slope of BPD traits and MDD symptoms was large. Consistent with previous cross-sectional 
reports (Kendler et al., 2011), common nonshared environmental factors also accounted for 
the correlated slopes between BPD traits and MDD symptoms. The large, nonshared 
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environmental correlation stands in contrast to the moderate to large genetic correlations 
between the growth parameters for BPD traits and AUD and DUD, and suggests that a 
markedly different process is driving the correlated rates of change between BPD traits and 
MDD symptoms. While complex processes involving both genetic and environmental 
factors likely contribute to the co-development of BPD traits and symptoms of commonly 
comorbid psychopathology, it is possible that environmental experiences (e.g., stressful life 
events, changes in relationships) have more pronounced effects on correlated changes in 
both BPD traits and MDD symptoms, with more gradual maturational changes in heritable 
characteristics (e.g., behavioral disinhibition) accounting for the majority of correlated 
changes between BPD traits and AUD and DUD symptoms.
On a broader level, the genetic correlations among the multiple forms of psychopathology 
are consistent with recent findings from molecular genetic research (Lichtenstein, Carlstrom, 
Rastam, Gillberg, & Anckarsater, 2010; Maier et al., 2015). The cross-disorder group from 
the Psychiatric Genetics Consortium, for instance, reported that some genetic risk factors 
seem to be shared across multiple disorders (attention deficit hyperactivity disorder, autism 
spectrum disorder, bipolar disorder, MDD, and schizophrenia; Smoller et al., 2013). Like 
previous work, our results provide support for the common cause and pathoplasty models 
across multiple forms of psychopathology. However, unlike existing molecular genetic work, 
we were able to model longitudinal relationships. This allowed us to begin disentangling 
common cause and pathoplasty at a finer level.
Given our results, an obvious question concerns identification of the common causes 
underlying the co-development between BPD traits and symptoms of other disorders. One 
possibility is common genetic variants influence both disorders – a possibility that should be 
explored in the cross-disorder group of the Psychiatric Genetics Consortium. As briefly 
alluded to above, a likely answer is that broad neurobehavioral processes such as negative 
emotionality, rejection sensitivity, emotional dysregulation, or behavioral disinhibition have 
non-specific effects and contribute to a diverse set of phenotypes including internalizing and 
externalizing disorders (Beauchaine, Gatzke-Kopp, & Mead, 2007; Iacono et al., 1999; 
Lenzenweger, 2010; Lilienfeld, 2003; Silk, Steinberg, & Morris, 2003; Young et al., 2009). 
With regard to behavioral disinhibition, the literature clearly documents elevated impulsivity 
in patients with BPD, AUD, and DUDs (Lee, Bagge, Schumacher, & Coffey, 2010; Links, 
Heslegrave, Mitton, Vanreekum, & Patrick, 1995; Wilson, Fertuck, Kwitel, Stanley, & 
Stanley, 2006) – suggesting that the latter serves as a process common to the two disorders 
(Bornovalova, Lejuez, Daughters, Rosenthal, & Lynch, 2005; Trull, Sher, Minks-Brown, 
Durbin, & Burr, 2000).
Common neurobiological changes throughout development may account for the correlated 
slopes between BPD traits and AUD and DUD symptoms. Developmental imaging studies 
suggest that the brain systems governing the socioemotional, cognitive, and decision-making 
processes that contribute to disinhibited behavior exhibit dramatic remodeling during middle 
and late adolescence (Spear, 2010; Wahlstrom, White, & Luciana, 2010). Distinct changes in 
adolescent neural processing of social and emotional information are thought to impact the 
functioning of the prefrontal cortex and subsequent self-regulation of motivational states and 
impulsive behavior (Ernst & Fudge, 2009; Spear, 2010; Steinberg, 2007). Notably, 
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development of these networks involve changes in the amygdala, nucleus accumbens, 
orbitofrontal cortex, medial prefrontal cortex, and superior temporal sulcus (Nelson, 
Leibenluft, McClure, & Pine, 2005) that occur at the same time as a dramatic remodeling of 
the dopaminergic neural reward system (Spear, 2000; Wahlstrom et al., 2010). The reward 
system also shows enhanced responsivity to anticipating and receiving rewards of 
disinhibited behavior in adolescence relative to adulthood (Bjork et al., 2004; Ernst & 
Fudge, 2009; Geier, Terwilliger, Teslovich, Velanova, & Luna, 2010; Joseph, Liu, Jiang, 
Lynam, & Kelly, 2009). Cross-sectionally, structural and functional variability in these 
systems has been documented in BPD, AUDs, and DUDs (Bowirrat & Oscar-Berman, 2005; 
Everitt & Robbins, 2005; Friedel, 2004; Hyman, Malenka, & Nestler, 2006; Kelley & 
Berridge, 2002; Koob, 1992; Makris et al., 2008; Wrase et al., 2007). Competition between 
the socioemotional and cognitive control system (Drevets & Raichle, 1998), altered timing 
in the maturation of these systems (Steinberg, 2007), or incomplete functional integration of 
neural signals implicated in the socioemotional and cognitive control systems (Stevens, 
2009) may be driving the correlated changes in BPD, AUD, and DUD as well. While the 
latter notion is speculative, data from large, epidemiological projects that include imaging 
(e.g., Adolescent Brain and Cognitive Development; National Consortium on Alcohol and 
Neurodevelopment in Adolescence) will be able to test it empirically.
Several findings were also consistent with the pathoplasty model. First, average levels of 
BPD traits were associated with greater increases in AUD and DUD symptoms, suggesting 
that BPD traits increase the likelihood of a transition from use to problem use and the 
escalation of AUD and DUD symptoms. Likewise, AUD and DUD symptoms were 
associated with a slower decline in BPD traits, suggesting substance use disorder symptoms 
disrupt maturational processes and contribute to the persistence of BPD traits. This result is 
consistent with other studies of BPD comorbidity in adolescence and adulthood (Burke & 
Stepp, 2012; Rohde, Lewinsohn, Kahler, Seeley, & Brown, 2001; Zanarini et al., 2004). For 
instance, Zanarini et al. (2004) reported that the absence of substance use disorders at a 6-
year follow-up was the strongest predictor of the remission of BPD in patients diagnosed 
with BPD.
Additionally, pathoplasty was evident for symptoms of MDD on AUD and DUD symptoms. 
That is, higher mean-levels of MDD symptoms were associated with greater increases in 
symptoms of AUD and DUD. Notably, this association was not reversed; that is, greater 
mean-levels of AUD and DUD symptoms were not associated with changes in MDD 
symptoms. Prior work on has provided mixed evidence on the temporal ordering of MDD 
and substance use problems, with some studies reporting that drug and alcohol use predicts 
MDD levels (Bovasso, 2001; Rohde et al., 2001; Stice, Burton, & Shaw, 2004), others that 
MDD symptoms predict substance use symptoms (Abraham & Fava, 1999), and still others 
reporting reciprocal relationships (Hettema, Prescott, & Kendler, 2003). Differences in 
sample composition and measurement approaches may account for many of the disparities. 
Our results suggest that unipolar mood symptoms are indicative of a more severe and 
persistent course of AUDs and DUDs.
When examining the evidence for the common cause and the pathoplasty hypotheses, two 
important observations should be underscored. First, it appears that the evidence for 
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pathoplasty is more associated with unique environmental factors, while the evidence for 
common cause is more associated with common/shared genetic factors, with the notable 
exception of the MDD intercept correlations with AUD and DUD linear slopes. Second, the 
magnitudes of the relationships that support the common cause hypothesis are slightly 
stronger than those that support the pathoplasty hypothesis.
Although unique, these findings are qualified by several limitations. First, nearly all 
participants were females of European American ancestry, limiting generalizability. BPD has 
traditionally been investigated in samples of middle to upper class, educated Caucasian 
females in psychiatric inpatient facilities (Silk, Lee, Hill, & Lohr, 1995; Zanarini, 
Frankenburg, Khera, & Bleichmar, 2001; Zanarini et al., 2002). However, it is possible that 
BPD-psychopathology relationships may differ across gender and ethnic groups, particularly 
considering evidence that rates of psychopathology, including personality disorders, differ 
across racial/ethnic groups (McGilloway, Hall, Lee, & Bhui, 2010; Turner & Gil, 2002). 
Second, the rate of BPD diagnosis is unknown in the current sample. Nevertheless, rates of 
similar disorders (e.g., antisocial personality disorder) are consistent with large, 
representative samples (Hamdi & Iacono, 2014). Third, the MBPD scale is a self-report 
questionnaire (albeit, well-validated) that provides a dimensional/trait rather than symptom 
measure of BPD. In contrast, MDD, AUD, and DUD symptoms were clinician-determined 
symptom counts. The differences in measurement introduce the potential concern of method 
effect that is not accounted for in the data, and likely reduces the effect sizes between BPD 
traits and the disorders given the different method of measurement. While interviews are 
often assumed to be superior to questionnaire measures, there is limited evidence for the 
incremental validity of one method over the other, though each approach has particular 
strengths and weaknesses (Hopwood et al., 2008). Ideally, the current study should be 
replicated using a multi-method (i.e., trait- and interview-based measures) approach. Finally, 
the current study was not set up to arbitrate between common cause and pathoplasty 
hypotheses (although the two may operate simultaneously).
Together, our results are indicative of meaningful co-developmental processes between BPD 
traits and MDD, AUD, and DUD symptoms. Moreover, our results further highlight the 
construct validity of the MBPD. The availability of a quantitative and dimensional measure 
of BPD traits that can be applied in a general population sample will further bridge the gap 
between psychopathology and normal behavior – a perspective consistent with the National 
Institute of Mental Health’s Research Domain Criteria framework (Insel et al., 2010). Our 
results set the stage for several future studies. The most apparent follow-up study would 
investigate temperamental and environmental processes that account for the genetic and 
environmental correlations between BPD traits and MDD, AUD, and DUD symptoms. One 
approach is to test if there is a corresponding reduction in the genetic correlation between 
BPD traits and AUD symptoms after accounting for a preexisting vulnerability (e.g., 
behavioral disinhibition). Next, this work should be replicated in another sample – 
preferably using a multi-method approach to the measurement of psychopathology. 
Likewise, this study should be replicated using males and more diverse samples. Finally, 
there is a clear need to extend these models of comorbidity into middle and late adulthood, 
as there is a clear drop-off in our understanding of BPD comorbidity past middle adulthood. 
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Exploration of these questions will provide further insight into etiological influences on 
BPD and its comorbidity with other psychopathology throughout the lifespan.
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Figure 1. 
Bivariate Growth Model for One Twin
Note: BPD refers to Borderline Personality Disorder traits, while AUD refers to Alcohol Use 
Disorder symptoms. In the full model, BPD traits, AUD, MDD, and DUD were included. An 
abbreviated figure is presented to increase clarity. Each assessment point is assumed to 
reflect an effect of general level of the phenotype/intercept (I), linear slope (S), and 
quadratic slope (Q), and assessment-specific additive genetic (A), shared environmental (C), 
and nonshared environmental effects (E). The intercept and slope effects are also 
decomposed into correlated additive genetic, shared environmental, and nonshared 
environmental effects. Subscripted numbers refer to the age of measurement, and numbers 
above the grey paths coefficients indicate fixed factor loadings for the growth parameters. 
Common Environmental effects were estimated in the fully saturated model but they were 
subsequently removed, as they did not improve the fit of the model.
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Figure 2. 
Predicted Growth trajectories for Borderline Personality Disorder traits, Major Depressive 
disorder symptoms, Alcohol Use Disorder symptoms, and Drug Use Disorder symptoms.
Note: Each point in the graphs represent expected means for the respective phenotype, while 
the black lines depict mean trajectories. The surrounding lines are 250 randomly sampled 
individuals from the dataset that illustrate variability around the mean trajectory. MDD, 
AUD, and DUD symptom variables underwent a log+1 transformation for all analyses, and 
log-transformed data are plotted above. MBPD was recoded to range between 1 (maximum 
possible score) and 0 (minimum possible score) [(MBPD individual score-min) (max-min) = 
(MBPD individual score-19)/57).
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